| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1136/BMJ.305.6866.1424 |
| P8608 | Fatcat ID | release_sruroqx3cbe6pfpkcrmszxsj6a |
| P953 | full work available at URL | https://europepmc.org/articles/PMC1883914 |
| https://europepmc.org/articles/PMC1883914?pdf=render | ||
| P932 | PMC publication ID | 1883914 |
| P698 | PubMed publication ID | 1486312 |
| P5875 | ResearchGate publication ID | 21670033 |
| P2093 | author name string | S. J. Russell | |
| R. E. Hawkins | |||
| M. B. Llewelyn | |||
| P2860 | cites work | A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals | Q24560010 |
| A humanized antibody that binds to the interleukin 2 receptor | Q24600912 | ||
| Selection of phage antibodies by binding affinity. Mimicking affinity maturation | Q28255489 | ||
| Reshaping human antibodies for therapy | Q28290936 | ||
| Adapting antibodies for clinical use. | Q33197771 | ||
| Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules | Q34408529 | ||
| Initial management of ingestions of toxic substances | Q36124804 | ||
| Primary antibody deficiency in adults | Q36482691 | ||
| Structure of solid tumors and their vasculature: implications for therapy with monoclonal antibodies | Q36657134 | ||
| Anti-Tac-H, a humanized antibody to the interleukin 2 receptor, prolongs primate cardiac allograft survival | Q37457154 | ||
| Humanized antibodies for antiviral therapy | Q37466235 | ||
| Reshaping a therapeutic CD4 antibody | Q37510930 | ||
| Monoclonal antibodies in diagnosis and therapy | Q37755851 | ||
| Systemic radiotherapy--the new frontier | Q37928557 | ||
| The First Bagshawe lecture. Towards generating cytotoxic agents at cancer sites | Q38694283 | ||
| Phase I immunotoxin trial in patients with B-cell lymphoma | Q40746210 | ||
| Treatment of rheumatoid arthritis with an anti-CD4 monoclonal antibody | Q40752113 | ||
| Anti-idiotypic monoclonal antibody to a T-cell chronic lymphatic leukemia. Characterization of the antibody, in vitro effector functions and results of therapy | Q40779148 | ||
| Therapeutic advantage of high-affinity anticarcinoma radioimmunoconjugates | Q41082594 | ||
| Monoclonal antibodies in sepsis and septic shock | Q43010911 | ||
| Intravenous immunoglobulins | Q43163451 | ||
| Reshaping a human monoclonal antibody to inhibit human respiratory syncytial virus infection in vivo | Q45874080 | ||
| Construction, binding properties, metabolism, and tumor targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49. | Q45951629 | ||
| Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group | Q46886444 | ||
| Monoclonal-Antibody Therapy in Systemic Vasculitis | Q61651745 | ||
| REMISSION INDUCTION IN NON-HODGKIN LYMPHOMA WITH RESHAPED HUMAN MONOCLONAL ANTIBODY CAMPATH-1H | Q61651778 | ||
| Anti-endotoxin monoclonal antibodies | Q68081134 | ||
| Monoclonal antibody to TNF in severe septic shock | Q68088154 | ||
| Anti-CD4 monoclonal antibody for relapsing polychondritis | Q68299867 | ||
| Treatment of inflammatory bowel disease with anti-CD4 monoclonal antibody | Q68312353 | ||
| Anti-CD4 therapy of acute rejection in long-term renal allograft recipients | Q68314596 | ||
| Treatment of severe systemic lupus erythematosus with anti-CD4 monoclonal antibody | Q68326745 | ||
| Randomized controlled trial of a monoclonal antibody against the interleukin-2 receptor (33B3.1) as compared with rabbit antithymocyte globulin for prophylaxis against rejection of renal allografts | Q68455768 | ||
| Immunosuppression in organ transplantation | Q68753442 | ||
| Treatment of B-cell lymphomas with anti-idiotype antibodies alone and in combination with alpha interferon | Q69053865 | ||
| Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody | Q69520763 | ||
| Phase I-II studies of yttrium-labeled antiferritin treatment for end-stage Hodgkin's disease, including Radiation Therapy Oncology Group 87-01 | Q70156002 | ||
| P433 | issue | 6866 | |
| P407 | language of work or name | English | Q1860 |
| P1104 | number of pages | 6 | |
| P304 | page(s) | 1424-1429 | |
| P577 | publication date | 1992-12-01 | |
| 1992-12-05 | |||
| P1433 | published in | The BMJ | Q546003 |
| P1476 | title | Principles of antibody therapy | |
| P478 | volume | 305 |
| Q42032204 | Cell and molecular mechanisms of pathogenesis and treatment of cancer |
| Q41193985 | Experimental antileukocyte interventions in cerebral ischemia |
| Q35790781 | Molecular biological design of novel antineoplastic therapies |
| Q73641337 | Monoclonal antibodies neutralizing the toxin II from Androctonus australis hector scorpion venom: usefulness of a synthetic, non-toxic analog |
| Q72994007 | Photodynamic therapy in lung cancer. A review |
| Q36163571 | Role of insulin-like growth factor 1 receptor signalling in cancer |
| Q34743728 | Therapeutic applications of monoclonal antibodies |
| Q41460854 | Vaccine strategies in non-Hodgkin's lymphomas |
Search more.